The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Open accessAbstract
The rare skin disorder pachyonychia congenita (PC) is an autosomal dominant syndrome that includes a disabling plantar keratoderma for which no satisfactory treatment is currently available. We have completed a phase Ib clinical trial for treatment of PC utilizing the first short-interfering RNA (siRNA)-based therapeutic for skin. This siRNA, called TD101, specifically and potently targets the keratin 6a (K6a) N171K mutant mRNA without affecting wild-type K6a mRNA. The safety and efficacy of TD101 was tested in a single-patient 17-week, prospective, double-blind, split-body, vehicle-controlled, dose-escalation trial. Randomly assigned solutions of TD101 or vehicle control were injected in symmetric plantar calluses on opposite feet. No adverse events occurred during the trial or in the 3-month washout period. Subjective patient assessment and physician clinical efficacy measures revealed regression of callus on the siRNA-treated, but not on the vehicle-treated foot. This trial represents the first time that siRNA has been used in a clinical setting to target a mutant gene or a genetic disorder, and the first use of siRNA in human skin. The callus regression seen on the patient's siRNA-treated foot appears sufficiently promising to warrant additional studies of siRNA in this and other dominant-negative skin diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
DEVINCENZO, J., CEHELSKY, J., ALVAREZ, R., ELBASHIR, S., HARBORTH, J., TOUDJARSKA, I., NECHEV, L., MURUGAIAH, V, VLIET, A., & VAISHNAW, A. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2007.11.009 · Cited by 247
Clinical and Pathological Features of Pachyonychia Congenita
Leachman, S. A., Kaspar, R. L., Fleckman, P., Florell, S. R., Smith, F. J. D., McLean, W. H. I., Lunny, D. P., Milstone, L. M., van Steensel, M. A. M., Munro, C. S., et al. (2005) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1111/j.1087-0024.2005.10202.x · Cited by 209
Self-citationStability Study of Unmodified siRNA and Relevance to Clinical Use
Hickerson, R. P., Vlassov, A. V., Wang, Q., Leake, D., Ilves, H., González-González, E., Contag, C. H., Johnston, B. H., & Kaspar, R. L. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0149 · Cited by 136
Self-citationTherapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita
Leachman, S. A., Hickerson, R. P., Hull, P. R., Smith, F. J. D., Milstone, L. M., Lane, E. B., Bale, S. J., Roop, D. R., McLean, W. H. I., & Kaspar, R. L. (2008) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2008.04.003 · Cited by 119
Self-citationSingle-Nucleotide-Specific siRNA Targeting in a Dominant-Negative Skin Model
Hickerson, R. P., Smith, F. J. D., Reeves, R. E., Contag, C. H., Leake, D., Leachman, S. A., Milstone, L. M., McLean, W. H. I., & Kaspar, R. L. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701060 · Cited by 115
Self-citationRNAi therapeutics: an update on delivery.
Nguyen, T. A., Menocal, E. M., Harborth, J., & Fruehauf, J. H. (2008) · PubMed · Cited by 111
The Business of RNAi Therapeutics
Haussecker, D. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.007 · Cited by 87
Cited by
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
LncRNA: A link between RNA and cancer
Yang, G., Lu, X., & Yuan, L. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.08.012 · Cited by 991
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
siRNA: Mechanism of action, challenges, and therapeutic approaches
Alshaer, W., Zureigat, H., Al Karaki, A., Al-Kadash, A., Gharaibeh, L., Hatmal, M. M., Aljabali, A. A. A., & Awidi, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174178 · Cited by 441
Keratin 6, 16 and 17—Critical Barrier Alarmin Molecules in Skin Wounds and Psoriasis
Zhang, X., Yin, M., & Zhang, L.-J. (2019) · Cells · doi:10.3390/cells8080807 · Cited by 417
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation
Zheng, D., Giljohann, D. A., Chen, D. L., Massich, M. D., Wang, X.-Q., Iordanov, H., Mirkin, C. A., & Paller, A. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118425109 · Cited by 409
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
Bobbin, M. L., & Rossi, J. J. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103633 · Cited by 353
Deng, Y., Wang, C. C., Choy, K. W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T. K. H., & Tang, T. (2014) · Gene · doi:10.1016/j.gene.2013.12.019 · Cited by 301
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
RNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 286
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
“completed [61]”
Epigenetics and Allergy: from Basic Mechanisms to Clinical Applications
Potaczek, D. P., Harb, H., Michel, S., Alhamwe, B. A., Renz, H., & Tost, J. (2017) · Epigenomics · doi:10.2217/epi-2016-0162 · Cited by 284
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 258
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50
Bhagat, L., Putta, M. R., Wang, D., Yu, D., Lan, T., Jiang, W., Sun, Z., Wang, H., Tang, J. X., La Monica, N., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200113t · Cited by 20
Metadata
- Authors
- Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., Smith, F. J., McLean, W. I., Milstone, L. M., & Kaspar, R. L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 18
- Issue
- 2
- Pages
- 442-446
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2057080391
- Cited by
- 265
- References
- 10
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.